Review



mca-yvadapk(dnp)-oh fluorogenic peptide substrate  (Bio-Techne corporation)


Bioz Verified Symbol Bio-Techne corporation is a verified supplier
Bioz Manufacturer Symbol Bio-Techne corporation manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Bio-Techne corporation mca-yvadapk(dnp)-oh fluorogenic peptide substrate
    Mca Yvadapk(dnp) Oh Fluorogenic Peptide Substrate, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 93/100, based on 49 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ace2+substrate/Mca-YVADAPK(Dnp)-OH+Fluorogenic+Peptide+Substrate/custom%40es007%4026498282
    Average 93 stars, based on 49 article reviews
    mca-yvadapk(dnp)-oh fluorogenic peptide substrate - by Bioz Stars, 2026-11
    93/100 stars

    Images

    Related Articles

    Drug discovery:

    Article Title: Discovery, validation, and prodrug design of an ACE2 activator for treating bacterial infection-induced lung inflammation
    Article Snippet: .. Calu-3 cells were treated serially with individual compounds contained within the Johns Hopkins Drug Library (JHDL), which includes a series of FDA-approved drugs [ ] (kindly provided by Dr. Jun O. Liu, Johns Hopkins University) at 10μM for 18h, and the ACE2 activity in cell culture medium was determined by measuring the fluorescence intensity of ACE2 substrate Mca-YVADAPK(Dnp)-OH (Catalog no. ES007; R&D Systems) [ ]. .. In brief, samples were diluted in assay buffer (50 mM MES, 300 mM NaCl, 10 nM ZnCl2, and 0.01% Brij-35 [pH 6.5]) and incubated with ACE2 substrate, with or without the ACE2 inhibitor MLN4760 (1 nM, catalog no. 62337; AnaSpec), at 37 °C for 45 min.

    Activity Assay:

    Article Title: Discovery, validation, and prodrug design of an ACE2 activator for treating bacterial infection-induced lung inflammation
    Article Snippet: .. Calu-3 cells were treated serially with individual compounds contained within the Johns Hopkins Drug Library (JHDL), which includes a series of FDA-approved drugs [ ] (kindly provided by Dr. Jun O. Liu, Johns Hopkins University) at 10μM for 18h, and the ACE2 activity in cell culture medium was determined by measuring the fluorescence intensity of ACE2 substrate Mca-YVADAPK(Dnp)-OH (Catalog no. ES007; R&D Systems) [ ]. .. In brief, samples were diluted in assay buffer (50 mM MES, 300 mM NaCl, 10 nM ZnCl2, and 0.01% Brij-35 [pH 6.5]) and incubated with ACE2 substrate, with or without the ACE2 inhibitor MLN4760 (1 nM, catalog no. 62337; AnaSpec), at 37 °C for 45 min.

    Article Title: Obese Male Mice Exposed to Early Life Stress Display Sympathetic Activation and Hypertension Independent of Circulating Angiotensin II
    Article Snippet: The protein concentrations of samples were determined by the Pierce BCA protein assay kit (ThermoFisher, Rockford, IL). .. ACE activity was measured using a fluorescence ACE assay, as previously described.26 For this, 20 μg of protein extract was diluted to 100 μL in assay buffer (50 mmol/L HEPES pH 8, 200 mmol/L NaCl, 10 μmol/L Zn acetate), and then 100 μL of the fluorogenic peptide substrate Mca- R- P–P- G- F- S- A- F- K(Dnp)- OH (R&D Systems, Netherlands) was added into each well at a concentration of 10 μmol/L in assay buffer with or without the ACE inhibitor lisinopril. .. The degradation of the fluorogenic peptide (fluorescence) was measured over time in a spectrophotometer (FLUOstar Omega; BMG LABTECH, Ortenberg, Germany) at 320 nm excitation and 405 nm emissions.

    Cell Culture:

    Article Title: Discovery, validation, and prodrug design of an ACE2 activator for treating bacterial infection-induced lung inflammation
    Article Snippet: .. Calu-3 cells were treated serially with individual compounds contained within the Johns Hopkins Drug Library (JHDL), which includes a series of FDA-approved drugs [ ] (kindly provided by Dr. Jun O. Liu, Johns Hopkins University) at 10μM for 18h, and the ACE2 activity in cell culture medium was determined by measuring the fluorescence intensity of ACE2 substrate Mca-YVADAPK(Dnp)-OH (Catalog no. ES007; R&D Systems) [ ]. .. In brief, samples were diluted in assay buffer (50 mM MES, 300 mM NaCl, 10 nM ZnCl2, and 0.01% Brij-35 [pH 6.5]) and incubated with ACE2 substrate, with or without the ACE2 inhibitor MLN4760 (1 nM, catalog no. 62337; AnaSpec), at 37 °C for 45 min.

    Fluorescence:

    Article Title: Discovery, validation, and prodrug design of an ACE2 activator for treating bacterial infection-induced lung inflammation
    Article Snippet: .. Calu-3 cells were treated serially with individual compounds contained within the Johns Hopkins Drug Library (JHDL), which includes a series of FDA-approved drugs [ ] (kindly provided by Dr. Jun O. Liu, Johns Hopkins University) at 10μM for 18h, and the ACE2 activity in cell culture medium was determined by measuring the fluorescence intensity of ACE2 substrate Mca-YVADAPK(Dnp)-OH (Catalog no. ES007; R&D Systems) [ ]. .. In brief, samples were diluted in assay buffer (50 mM MES, 300 mM NaCl, 10 nM ZnCl2, and 0.01% Brij-35 [pH 6.5]) and incubated with ACE2 substrate, with or without the ACE2 inhibitor MLN4760 (1 nM, catalog no. 62337; AnaSpec), at 37 °C for 45 min.

    Article Title: Obese Male Mice Exposed to Early Life Stress Display Sympathetic Activation and Hypertension Independent of Circulating Angiotensin II
    Article Snippet: The protein concentrations of samples were determined by the Pierce BCA protein assay kit (ThermoFisher, Rockford, IL). .. ACE activity was measured using a fluorescence ACE assay, as previously described.26 For this, 20 μg of protein extract was diluted to 100 μL in assay buffer (50 mmol/L HEPES pH 8, 200 mmol/L NaCl, 10 μmol/L Zn acetate), and then 100 μL of the fluorogenic peptide substrate Mca- R- P–P- G- F- S- A- F- K(Dnp)- OH (R&D Systems, Netherlands) was added into each well at a concentration of 10 μmol/L in assay buffer with or without the ACE inhibitor lisinopril. .. The degradation of the fluorogenic peptide (fluorescence) was measured over time in a spectrophotometer (FLUOstar Omega; BMG LABTECH, Ortenberg, Germany) at 320 nm excitation and 405 nm emissions.

    Concentration Assay:

    Article Title: Obese Male Mice Exposed to Early Life Stress Display Sympathetic Activation and Hypertension Independent of Circulating Angiotensin II
    Article Snippet: The protein concentrations of samples were determined by the Pierce BCA protein assay kit (ThermoFisher, Rockford, IL). .. ACE activity was measured using a fluorescence ACE assay, as previously described.26 For this, 20 μg of protein extract was diluted to 100 μL in assay buffer (50 mmol/L HEPES pH 8, 200 mmol/L NaCl, 10 μmol/L Zn acetate), and then 100 μL of the fluorogenic peptide substrate Mca- R- P–P- G- F- S- A- F- K(Dnp)- OH (R&D Systems, Netherlands) was added into each well at a concentration of 10 μmol/L in assay buffer with or without the ACE inhibitor lisinopril. .. The degradation of the fluorogenic peptide (fluorescence) was measured over time in a spectrophotometer (FLUOstar Omega; BMG LABTECH, Ortenberg, Germany) at 320 nm excitation and 405 nm emissions.



    Similar Products

    90
    AnaSpec fluorogenic ace2 substrate mca-apk(dnp)
    Participant demographics and health characteristics.
    Fluorogenic Ace2 Substrate Mca Apk(dnp), supplied by AnaSpec, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ace2+substrate/sensolyte+390+ace2+activity+assay+kit/pmc11826374-82-15-19
    Average 90 stars, based on 1 article reviews
    fluorogenic ace2 substrate mca-apk(dnp) - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    93
    BPS Bioscience peptide substrate nα
    Participant demographics and health characteristics.
    Peptide Substrate Nα, supplied by BPS Bioscience, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ace2+substrate/ACE2-Spike+TR-FRET+Buffer/10__1021_slash_acscatal__4c04695-32-2-10
    Average 93 stars, based on 1 article reviews
    peptide substrate nα - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    93
    BPS Bioscience fret based peptide substrate nα
    Participant demographics and health characteristics.
    Fret Based Peptide Substrate Nα, supplied by BPS Bioscience, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ace2+substrate/ACE2-Spike+TR-FRET+Buffer/10__1021_slash_acscatal__4c04695-32-1-10
    Average 93 stars, based on 1 article reviews
    fret based peptide substrate nα - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    90
    AnaSpec fluorogenic ace2 substrate mca-apk(dnp
    A) overall view of <t>anti-ACE2</t> IgG, IgA, and IgM antibodies of the full cohort including longitudinal sampling. B) Quantitative Venn diagram representation of the distribution between IgM, IgA, and IgG ACE2 autoantibodies in the overall cohort of ACE2-positive individuals. C) IgG, IgA, and IgM anti-ACE2 antibodies and associated threshold. IgG and IgA threshold was set at two cycles of 2 standard deviations (SD) from the mean of the presumed negative distribution. IgM threshold was set by a first cycle at 2SD and a second at 1SD from the mean of the presumed negative distribution.
    Fluorogenic Ace2 Substrate Mca Apk(dnp, supplied by AnaSpec, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ace2+substrate/sensolyte+390+ace2+activity+assay+kit/med_rxiv__2024__11__18__24317488-239-14-18
    Average 90 stars, based on 1 article reviews
    fluorogenic ace2 substrate mca-apk(dnp - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    90
    Bachem artificial ace2 substrate mca-apk-dnp
    A) overall view of <t>anti-ACE2</t> IgG, IgA, and IgM antibodies of the full cohort including longitudinal sampling. B) Quantitative Venn diagram representation of the distribution between IgM, IgA, and IgG ACE2 autoantibodies in the overall cohort of ACE2-positive individuals. C) IgG, IgA, and IgM anti-ACE2 antibodies and associated threshold. IgG and IgA threshold was set at two cycles of 2 standard deviations (SD) from the mean of the presumed negative distribution. IgM threshold was set by a first cycle at 2SD and a second at 1SD from the mean of the presumed negative distribution.
    Artificial Ace2 Substrate Mca Apk Dnp, supplied by Bachem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ace2+substrate/abz+ser+pro+3+nitro+tyr+oh++m+2660+for+ace2/us12123036-604-5-8
    Average 90 stars, based on 1 article reviews
    artificial ace2 substrate mca-apk-dnp - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    94
    BPS Bioscience fluorogenic substrate
    A) overall view of <t>anti-ACE2</t> IgG, IgA, and IgM antibodies of the full cohort including longitudinal sampling. B) Quantitative Venn diagram representation of the distribution between IgM, IgA, and IgG ACE2 autoantibodies in the overall cohort of ACE2-positive individuals. C) IgG, IgA, and IgM anti-ACE2 antibodies and associated threshold. IgG and IgA threshold was set at two cycles of 2 standard deviations (SD) from the mean of the presumed negative distribution. IgM threshold was set by a first cycle at 2SD and a second at 1SD from the mean of the presumed negative distribution.
    Fluorogenic Substrate, supplied by BPS Bioscience, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ace2+substrate/ACE2+Inhibitor+Screening+Assay+Kit/us11963955-1339-11-18
    Average 94 stars, based on 1 article reviews
    fluorogenic substrate - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    93
    R&D Systems ace2 substrate
    A) overall view of <t>anti-ACE2</t> IgG, IgA, and IgM antibodies of the full cohort including longitudinal sampling. B) Quantitative Venn diagram representation of the distribution between IgM, IgA, and IgG ACE2 autoantibodies in the overall cohort of ACE2-positive individuals. C) IgG, IgA, and IgM anti-ACE2 antibodies and associated threshold. IgG and IgA threshold was set at two cycles of 2 standard deviations (SD) from the mean of the presumed negative distribution. IgM threshold was set by a first cycle at 2SD and a second at 1SD from the mean of the presumed negative distribution.
    Ace2 Substrate, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ace2+substrate/Mca-YVADAPK(Dnp)-OH+Fluorogenic+Peptide+Substrate/pm38602847-151-18-22
    Average 93 stars, based on 1 article reviews
    ace2 substrate - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    90
    AnaSpec ace2 fluorogenic substrate mca-ala-pro-lys(dnp)-oh
    A) overall view of <t>anti-ACE2</t> IgG, IgA, and IgM antibodies of the full cohort including longitudinal sampling. B) Quantitative Venn diagram representation of the distribution between IgM, IgA, and IgG ACE2 autoantibodies in the overall cohort of ACE2-positive individuals. C) IgG, IgA, and IgM anti-ACE2 antibodies and associated threshold. IgG and IgA threshold was set at two cycles of 2 standard deviations (SD) from the mean of the presumed negative distribution. IgM threshold was set by a first cycle at 2SD and a second at 1SD from the mean of the presumed negative distribution.
    Ace2 Fluorogenic Substrate Mca Ala Pro Lys(dnp) Oh, supplied by AnaSpec, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ace2+substrate/sensolyte+390+ace2+activity+assay+kit/pmc11032047-93-4-5
    Average 90 stars, based on 1 article reviews
    ace2 fluorogenic substrate mca-ala-pro-lys(dnp)-oh - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    86
    Danaher Inc ace2 protease substrate solution
    Potato PI fractions inhibit a range of proteases relevant to virus infection and tissue damage
    Ace2 Protease Substrate Solution, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ace2+substrate/pmc10963447-304-25-29
    Average 86 stars, based on 1 article reviews
    ace2 protease substrate solution - by Bioz Stars, 2026-11
    86/100 stars
      Buy from Supplier

    Image Search Results


    Participant demographics and health characteristics.

    Journal: The FASEB Journal

    Article Title: Autoantibodies targeting angiotensin‐converting enzyme 2 are prevalent and not induced by SARS ‐ CoV ‐2 infection

    doi: 10.1096/fj.202402694R

    Figure Lengend Snippet: Participant demographics and health characteristics.

    Article Snippet: 10 μL of neutralized samples was transferred to 96‐well black plates containing 15 μM of fluorogenic ACE2 substrate Mca‐APK(Dnp) (Anaspec, Fremont, CA, USA, cat. AS‐60757), to a final concentration of 11.25 μM.

    Techniques: Infection, Biomarker Discovery

    Overview of ACE2 serology results and establishment of seropositivity thresholds. (A) Overall view of anti‐ACE2 IgG, IgA, and IgM antibodies of the full cohort, including longitudinal sampling. (B) Quantitative Venn diagram representation of the distribution between IgM, IgA, and IgG ACE2 autoantibodies in the overall cohort of ACE2‐positive individuals. (C) IgG, IgA, and IgM anti‐ACE2 antibodies and associated threshold. IgG and IgA threshold was set at two cycles of 2 standard deviations (SD) from the mean of the presumed negative distribution. IgM threshold was set by a first cycle at 2SD and a second at 1SD from the mean of the presumed negative distribution.

    Journal: The FASEB Journal

    Article Title: Autoantibodies targeting angiotensin‐converting enzyme 2 are prevalent and not induced by SARS ‐ CoV ‐2 infection

    doi: 10.1096/fj.202402694R

    Figure Lengend Snippet: Overview of ACE2 serology results and establishment of seropositivity thresholds. (A) Overall view of anti‐ACE2 IgG, IgA, and IgM antibodies of the full cohort, including longitudinal sampling. (B) Quantitative Venn diagram representation of the distribution between IgM, IgA, and IgG ACE2 autoantibodies in the overall cohort of ACE2‐positive individuals. (C) IgG, IgA, and IgM anti‐ACE2 antibodies and associated threshold. IgG and IgA threshold was set at two cycles of 2 standard deviations (SD) from the mean of the presumed negative distribution. IgM threshold was set by a first cycle at 2SD and a second at 1SD from the mean of the presumed negative distribution.

    Article Snippet: 10 μL of neutralized samples was transferred to 96‐well black plates containing 15 μM of fluorogenic ACE2 substrate Mca‐APK(Dnp) (Anaspec, Fremont, CA, USA, cat. AS‐60757), to a final concentration of 11.25 μM.

    Techniques: Sampling

    Influence of clinical features and demographic characteristics on ACE2 autoantibodies prevalence. Odd ratios (OR) and 95% confidence interval (CI) were calculated for demographic characteristics and clinical features for individuals in relation to (A) IgG, (B) IgA and (C) IgM ACE2 autoantibodies. A table with a complete list of OR and 95% CI is available in the Table . The OR (CI95) are shown here on a log10 formatted axis.

    Journal: The FASEB Journal

    Article Title: Autoantibodies targeting angiotensin‐converting enzyme 2 are prevalent and not induced by SARS ‐ CoV ‐2 infection

    doi: 10.1096/fj.202402694R

    Figure Lengend Snippet: Influence of clinical features and demographic characteristics on ACE2 autoantibodies prevalence. Odd ratios (OR) and 95% confidence interval (CI) were calculated for demographic characteristics and clinical features for individuals in relation to (A) IgG, (B) IgA and (C) IgM ACE2 autoantibodies. A table with a complete list of OR and 95% CI is available in the Table . The OR (CI95) are shown here on a log10 formatted axis.

    Article Snippet: 10 μL of neutralized samples was transferred to 96‐well black plates containing 15 μM of fluorogenic ACE2 substrate Mca‐APK(Dnp) (Anaspec, Fremont, CA, USA, cat. AS‐60757), to a final concentration of 11.25 μM.

    Techniques:

    Persistence of autoantibodies in serum over time and association with previous SARS‐CoV‐2 infection. (A) Some individuals had one or two follow‐up samples. ACE2 IgG, IgA, IgM is shown longitudinally (Follow up 1 ( n = 120), median time between draws (SD) = 35 days (10), Follow up 2 ( n = 35), median time between draws (SD) = 37 days (6)). (B) IgG, IgA, and IgM ACE2 autoantibodies levels are shown for individuals who never had SARS‐CoV‐2 and for individuals who had serological markers of SARS‐CoV‐2 infection and/or self‐reported a SARS‐CoV‐2 infection. Unpaired two‐sided Wilcoxon test was used to establish statistical significance ( n = 464), p ≤ 0.05 (*), p ≤ 0.01 (**), p ≤ 0.001 (***), p ≤ 0.0001 (****).

    Journal: The FASEB Journal

    Article Title: Autoantibodies targeting angiotensin‐converting enzyme 2 are prevalent and not induced by SARS ‐ CoV ‐2 infection

    doi: 10.1096/fj.202402694R

    Figure Lengend Snippet: Persistence of autoantibodies in serum over time and association with previous SARS‐CoV‐2 infection. (A) Some individuals had one or two follow‐up samples. ACE2 IgG, IgA, IgM is shown longitudinally (Follow up 1 ( n = 120), median time between draws (SD) = 35 days (10), Follow up 2 ( n = 35), median time between draws (SD) = 37 days (6)). (B) IgG, IgA, and IgM ACE2 autoantibodies levels are shown for individuals who never had SARS‐CoV‐2 and for individuals who had serological markers of SARS‐CoV‐2 infection and/or self‐reported a SARS‐CoV‐2 infection. Unpaired two‐sided Wilcoxon test was used to establish statistical significance ( n = 464), p ≤ 0.05 (*), p ≤ 0.01 (**), p ≤ 0.001 (***), p ≤ 0.0001 (****).

    Article Snippet: 10 μL of neutralized samples was transferred to 96‐well black plates containing 15 μM of fluorogenic ACE2 substrate Mca‐APK(Dnp) (Anaspec, Fremont, CA, USA, cat. AS‐60757), to a final concentration of 11.25 μM.

    Techniques: Infection

    Effect of ACE2 autoantibodies on ACE2 enzymatic activity and SARS‐CoV‐2 spike‐ACE2 binding. (A) ACE2 autoantibodies levels (IgG, IgA, IgM) in a subset of samples for which ACE2 enzymatic activity was assessed. (B) Levels of ACE2 enzymatic activity in individuals who had IgG and/or IgA and/or IgM ACE2 autoantibodies in contrast to the individuals who had no detectable ACE2 autoantibodies. (C) Levels of ACE2 enzymatic activity in individuals who self‐reported a SARS‐CoV‐2 infection and/or had serological markers of previous infection. (D) ACE2 autoantibodies levels in a subset of samples in which ACE2 and spike interaction was assessed. (E) Anti‐Spike IgG antibodies levels pre‐ and post‐depletion in sera. (F) % inhibition representing the ability of the sera to inhibit spike and ACE2 interaction pre‐ and post‐depletion. (G) % inhibition representing the ability of the sera to inhibit spike and ACE2 interaction in individuals who had IgG and/or IgA and/or IgM ACE2 autoantibodies above threshold in contrast to the individuals who had no detectable ACE2 autoantibodies. (H) Linear correlation between the ability of sera to inhibit Spike and ACE2 binding and the levels of Spike IgG antibodies in depleted sera. Unpaired two‐sided Wilcoxon test was used to establish statistical significance where applicable, p ≤ 0.05 (*), p ≤ 0.01 (**), p ≤ 0.001 (***), p ≤ 0.0001 (****).

    Journal: The FASEB Journal

    Article Title: Autoantibodies targeting angiotensin‐converting enzyme 2 are prevalent and not induced by SARS ‐ CoV ‐2 infection

    doi: 10.1096/fj.202402694R

    Figure Lengend Snippet: Effect of ACE2 autoantibodies on ACE2 enzymatic activity and SARS‐CoV‐2 spike‐ACE2 binding. (A) ACE2 autoantibodies levels (IgG, IgA, IgM) in a subset of samples for which ACE2 enzymatic activity was assessed. (B) Levels of ACE2 enzymatic activity in individuals who had IgG and/or IgA and/or IgM ACE2 autoantibodies in contrast to the individuals who had no detectable ACE2 autoantibodies. (C) Levels of ACE2 enzymatic activity in individuals who self‐reported a SARS‐CoV‐2 infection and/or had serological markers of previous infection. (D) ACE2 autoantibodies levels in a subset of samples in which ACE2 and spike interaction was assessed. (E) Anti‐Spike IgG antibodies levels pre‐ and post‐depletion in sera. (F) % inhibition representing the ability of the sera to inhibit spike and ACE2 interaction pre‐ and post‐depletion. (G) % inhibition representing the ability of the sera to inhibit spike and ACE2 interaction in individuals who had IgG and/or IgA and/or IgM ACE2 autoantibodies above threshold in contrast to the individuals who had no detectable ACE2 autoantibodies. (H) Linear correlation between the ability of sera to inhibit Spike and ACE2 binding and the levels of Spike IgG antibodies in depleted sera. Unpaired two‐sided Wilcoxon test was used to establish statistical significance where applicable, p ≤ 0.05 (*), p ≤ 0.01 (**), p ≤ 0.001 (***), p ≤ 0.0001 (****).

    Article Snippet: 10 μL of neutralized samples was transferred to 96‐well black plates containing 15 μM of fluorogenic ACE2 substrate Mca‐APK(Dnp) (Anaspec, Fremont, CA, USA, cat. AS‐60757), to a final concentration of 11.25 μM.

    Techniques: Activity Assay, Binding Assay, Infection, Inhibition

    A) overall view of anti-ACE2 IgG, IgA, and IgM antibodies of the full cohort including longitudinal sampling. B) Quantitative Venn diagram representation of the distribution between IgM, IgA, and IgG ACE2 autoantibodies in the overall cohort of ACE2-positive individuals. C) IgG, IgA, and IgM anti-ACE2 antibodies and associated threshold. IgG and IgA threshold was set at two cycles of 2 standard deviations (SD) from the mean of the presumed negative distribution. IgM threshold was set by a first cycle at 2SD and a second at 1SD from the mean of the presumed negative distribution.

    Journal: medRxiv

    Article Title: Autoantibodies Targeting Angiotensin Converting Enzyme 2 Are Prevalent and Not Induced by SARS-CoV-2 Infection

    doi: 10.1101/2024.11.18.24317488

    Figure Lengend Snippet: A) overall view of anti-ACE2 IgG, IgA, and IgM antibodies of the full cohort including longitudinal sampling. B) Quantitative Venn diagram representation of the distribution between IgM, IgA, and IgG ACE2 autoantibodies in the overall cohort of ACE2-positive individuals. C) IgG, IgA, and IgM anti-ACE2 antibodies and associated threshold. IgG and IgA threshold was set at two cycles of 2 standard deviations (SD) from the mean of the presumed negative distribution. IgM threshold was set by a first cycle at 2SD and a second at 1SD from the mean of the presumed negative distribution.

    Article Snippet: 10uL of neutralized samples were transferred to 96-well black plates containing 15 uM of fluorogenic ACE2 substrate Mca-APK(Dnp) (Anaspec, Fremont, CA, USA, cat. AS-60757), to a final concentration of 11.25 uM ( ).

    Techniques: Sampling

    Odd ratios (OR) and 95% confidence interval (CI) were calculated for demographi characteristics and clinical features for individuals in relation to A) IgG, B) IgA and C) IgM ACE2 autoantibodies. A table with a complete list of OR and 95% CI is available in the supplementary material (Supp. ). The OR (CI95) are shown here on a log10 formatted axis.

    Journal: medRxiv

    Article Title: Autoantibodies Targeting Angiotensin Converting Enzyme 2 Are Prevalent and Not Induced by SARS-CoV-2 Infection

    doi: 10.1101/2024.11.18.24317488

    Figure Lengend Snippet: Odd ratios (OR) and 95% confidence interval (CI) were calculated for demographi characteristics and clinical features for individuals in relation to A) IgG, B) IgA and C) IgM ACE2 autoantibodies. A table with a complete list of OR and 95% CI is available in the supplementary material (Supp. ). The OR (CI95) are shown here on a log10 formatted axis.

    Article Snippet: 10uL of neutralized samples were transferred to 96-well black plates containing 15 uM of fluorogenic ACE2 substrate Mca-APK(Dnp) (Anaspec, Fremont, CA, USA, cat. AS-60757), to a final concentration of 11.25 uM ( ).

    Techniques:

    A) Some individuals had one or two follow-up samples. ACE2 IgG, IgA, IgM is shown longitudinally (Follow up 1 (n=120), median time between draws (SD) = 35 days , Follow up 2 (n=35), median time between draws (SD) = 37 days ). B) IgG, IgA, IgM ACE2 autoantibodies levels are shown for individuals who never had SARS-CoV-2 and for individuals who had serological markers of SARS-CoV-2 infection and/or self-reported a SARS-CoV-2 infection. Unpaired two-sided Wilcoxon test was used to establish statistical significance (n=464), * p< 0.05, ** p< 0.01, ***p<0.001, ****p<0.0001.

    Journal: medRxiv

    Article Title: Autoantibodies Targeting Angiotensin Converting Enzyme 2 Are Prevalent and Not Induced by SARS-CoV-2 Infection

    doi: 10.1101/2024.11.18.24317488

    Figure Lengend Snippet: A) Some individuals had one or two follow-up samples. ACE2 IgG, IgA, IgM is shown longitudinally (Follow up 1 (n=120), median time between draws (SD) = 35 days , Follow up 2 (n=35), median time between draws (SD) = 37 days ). B) IgG, IgA, IgM ACE2 autoantibodies levels are shown for individuals who never had SARS-CoV-2 and for individuals who had serological markers of SARS-CoV-2 infection and/or self-reported a SARS-CoV-2 infection. Unpaired two-sided Wilcoxon test was used to establish statistical significance (n=464), * p< 0.05, ** p< 0.01, ***p<0.001, ****p<0.0001.

    Article Snippet: 10uL of neutralized samples were transferred to 96-well black plates containing 15 uM of fluorogenic ACE2 substrate Mca-APK(Dnp) (Anaspec, Fremont, CA, USA, cat. AS-60757), to a final concentration of 11.25 uM ( ).

    Techniques: Infection

    A) ACE2 autoantibodies levels (IgG, IgA, IgM) in a subset of samples for which ACE2 enzymatic activity was assessed. B) Levels of ACE2 enzymatic activity in individuals who had IgG and/or IgA and/or IgM ACE2 autoantibodies in contrast to the individuals who had no detectable ACE2 autoantibodies. C) Levels of ACE2 enzymatic activity in individuals who self-reported a SARS-CoV-2 infection and/or had serological markers of previous infection. D) ACE2 autoantibodies levels in a subset of samples in which ACE2 and spike interaction was assessed. E) Anti-Spike IgG antibodies levels pre-and post-depletion in sera. F) % inhibition representing the ability of the sera to inhibit Spike and ACE2 interaction pre-and post-depletion. G) % inhibition representing the ability of the sera to inhibit Spike and ACE2 interaction in individuals who had IgG and/or IgA and/or IgM ACE2 autoantibodies above threshold in contrast to the individuals who had no detectable ACE2 autoantibodies. H) Linear correlation between the ability of sera to inhibit Spike and ACE2 binding and the levels of Spike IgG antibodies in depleted sera. Unpaired two-sided Wilcoxon test was used to establish statistical significance where applicable, * p< 0.05, ** p< 0.01, ***p<0.001, ****p<0.0001.

    Journal: medRxiv

    Article Title: Autoantibodies Targeting Angiotensin Converting Enzyme 2 Are Prevalent and Not Induced by SARS-CoV-2 Infection

    doi: 10.1101/2024.11.18.24317488

    Figure Lengend Snippet: A) ACE2 autoantibodies levels (IgG, IgA, IgM) in a subset of samples for which ACE2 enzymatic activity was assessed. B) Levels of ACE2 enzymatic activity in individuals who had IgG and/or IgA and/or IgM ACE2 autoantibodies in contrast to the individuals who had no detectable ACE2 autoantibodies. C) Levels of ACE2 enzymatic activity in individuals who self-reported a SARS-CoV-2 infection and/or had serological markers of previous infection. D) ACE2 autoantibodies levels in a subset of samples in which ACE2 and spike interaction was assessed. E) Anti-Spike IgG antibodies levels pre-and post-depletion in sera. F) % inhibition representing the ability of the sera to inhibit Spike and ACE2 interaction pre-and post-depletion. G) % inhibition representing the ability of the sera to inhibit Spike and ACE2 interaction in individuals who had IgG and/or IgA and/or IgM ACE2 autoantibodies above threshold in contrast to the individuals who had no detectable ACE2 autoantibodies. H) Linear correlation between the ability of sera to inhibit Spike and ACE2 binding and the levels of Spike IgG antibodies in depleted sera. Unpaired two-sided Wilcoxon test was used to establish statistical significance where applicable, * p< 0.05, ** p< 0.01, ***p<0.001, ****p<0.0001.

    Article Snippet: 10uL of neutralized samples were transferred to 96-well black plates containing 15 uM of fluorogenic ACE2 substrate Mca-APK(Dnp) (Anaspec, Fremont, CA, USA, cat. AS-60757), to a final concentration of 11.25 uM ( ).

    Techniques: Activity Assay, Infection, Inhibition, Binding Assay

    Potato PI fractions inhibit a range of proteases relevant to virus infection and tissue damage

    Journal: Journal of Molecular Medicine (Berlin, Germany)

    Article Title: Novel high-yield potato protease inhibitor panels block a wide array of proteases involved in viral infection and crucial tissue damage

    doi: 10.1007/s00109-024-02423-x

    Figure Lengend Snippet: Potato PI fractions inhibit a range of proteases relevant to virus infection and tissue damage

    Article Snippet: Concentrations between 100 nM and 1 μM were used for fractions 1–5 and incubated for 6 h at 37 °C, whereafter 2 µL of the ACE2 protease substrate solution (Abcam, UK #111,750) was added.

    Techniques: Virus, Infection

    Inhibition of ACE2 activity in Vero E6 cells by the PI fractions. A – E Proteolytic activity of ACE2 measured from fractions 1–5 in Vero E6 cells. All individual experiments were performed in triplicate. Significance was tested using Students’ test. p values are indicated as **** p < 0.0001, *** p < 0.001, ** p < 0.01, and * p < 0.05

    Journal: Journal of Molecular Medicine (Berlin, Germany)

    Article Title: Novel high-yield potato protease inhibitor panels block a wide array of proteases involved in viral infection and crucial tissue damage

    doi: 10.1007/s00109-024-02423-x

    Figure Lengend Snippet: Inhibition of ACE2 activity in Vero E6 cells by the PI fractions. A – E Proteolytic activity of ACE2 measured from fractions 1–5 in Vero E6 cells. All individual experiments were performed in triplicate. Significance was tested using Students’ test. p values are indicated as **** p < 0.0001, *** p < 0.001, ** p < 0.01, and * p < 0.05

    Article Snippet: Concentrations between 100 nM and 1 μM were used for fractions 1–5 and incubated for 6 h at 37 °C, whereafter 2 µL of the ACE2 protease substrate solution (Abcam, UK #111,750) was added.

    Techniques: Inhibition, Activity Assay

    Inhibitory activity of potato PI fractions against enzymes in viral replication and tissue damage

    Journal: Journal of Molecular Medicine (Berlin, Germany)

    Article Title: Novel high-yield potato protease inhibitor panels block a wide array of proteases involved in viral infection and crucial tissue damage

    doi: 10.1007/s00109-024-02423-x

    Figure Lengend Snippet: Inhibitory activity of potato PI fractions against enzymes in viral replication and tissue damage

    Article Snippet: Concentrations between 100 nM and 1 μM were used for fractions 1–5 and incubated for 6 h at 37 °C, whereafter 2 µL of the ACE2 protease substrate solution (Abcam, UK #111,750) was added.

    Techniques: Activity Assay